Various PEP and OPEP devices are available in the market, with differing degrees of device-specific complexity, resistance settings, and usability. The devices must be cleaned regularly to avoid contamination from infections inhaled into the device or transmitted through contact with the mouthpiece. The development of these compact, low-cost, and portable devices for patients has made significant progress in administering therapy under the supervision of a clinical practitioner or 'as-needed' basis. These advancements have been accompanied by research that enhanced the understanding of the working of therapies and the ways it can be used to improve device performance. There are already OPEP devices that are typically reusable and require daily, if not frequent, cleaning to avoid infection by acting as reservoirs of potentially dangerous organisms. In response, the UL-OPEP, a daily disposable OPEP device, was created to reduce the danger of contamination and eliminate the requirement for cleaning devices. The disposable OPEP device helps maintain patients' lung function after short-term use (less than one month) and received excellent feedback for its functioning while lowering the danger of airway contamination caused by poor cleaning. Clinical evidence suggests that various OPEP devices help patients suffering from stable COPD and cystic fibrosis improve short-term lung function, exercise capacity, and quality of life, in addition to clearing mucus. For instance, in June 2019, Solopep announced that the company had developed a disposable OPEP device for patients affected by cystic fibrosis, bronchiectasis, and COPD. Technological advancement such as the development of disposable OPEP devices is driving the OPEP devices market.
With new features and advanced technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific oscillating positive expiratory pressure (OPEP) devices market a notable CAGR during the forecast period.
Asia Pacific Oscillating Positive Expiratory Pressure (OPEP) Devices Market Segmentation
The Asia Pacific oscillating positive expiratory pressure (OPEP) devices market is segmented on the basis of product, indication, distribution channel, and country. Based on product, the market is segmented into mouthpiece PEP devices, face mask PEP devices, and bottle PEP devices. In 2021, the mouthpiece PEP devices segment accounted for the largest market share; and it is likely to register the highest CAGR during the forecast period. Based on indication, the market is categorized into chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiectasis, cystic fibrosis, and others. In 2021, the chronic obstructive pulmonary disease (COPD) segment accounted for the largest share of the market; however, the asthma segment is likely to register the highest CAGR during the forecast period. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2021, the hospital pharmacies segment held the largest market share; however, the retail pharmacies segment is expected to register the highest CAGR in the market during the forecast period. Further, based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. In 2021, China held the largest market share, and India is expected to register the highest CAGR during the forecast period.
Allergan Plc.; PARI GmbH; Smiths Medical; AirPhysio; Mercury Medical; Able Healthcare; and Medica Holdings, LLC are among some of the leading companies operating in the Asia Pacific oscillating positive expiratory pressure (OPEP) devices market.